ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0399

External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0714

Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort

(0711–0730) Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0368

Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0576

Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0761

Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0750

Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0346

Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk

(0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0447

Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0059

Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner

(0049–0066) Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0246

Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0338

Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis

(0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0432

Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0764

Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0305

From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy

(0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0509

Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation

(0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].